Products

ASX
LCT 0.049   Last updated EOD 16th November 2018
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

Pipeline

LCT is developing new products in line with its mission to improve the well-being of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which include naturally occurring cells to restore function. 

Pericyte Protective Agent

"Pericytes hold great promise for clinical neuropharmacology: identifying molecules that promote pericyte health, especially in the injured, diseased, or aging human brain, may provide a novel strategy for the promotion of brain health."

Rustenhoven et al in Trends in Pharmacological Sciences (2016), 38, 291-304.

 

LCT is making good research progress towards identifying a novel active agent derived from the chemical secretions of NTCELL (encapsulated choroid plexus cells).

 

Initial results studying the effects of NTCELL on human pericytes in vitro, show that choroid plexus media/capsules were beneficial in enhancing pericyte survival. This could not only explain the mechanism of action for NTCELL but could allow us to identify the key neuroprotectant substances that have neuroprotective activity.

 

Research to date indicates that the pericyte protective agent secreted by NTCELL is small molecule and can be extracted from NTCELL in the methanol fraction. The next step is to identify and synthesise the compound.

PRINT PAGE print-icon
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.